The Center for Health + Technology has become a leading model for getting new treatments to patients faster and more equitably.
12
The number of neurological drugs and devices brought to market with CHeT’s help—including every FDA-approved treatment for Huntington’s disease.
When a new drug or device for a brain or nerve disorder reaches patients, there’s a good chance a URochester team helped it get there. For nearly 40 years, the University of Rochester’s Center for Health + Technology (CHeT) has been a behind-the-scenes force in neurological drug discovery. That work has resulted in helping to bring 12 FDA-approved drugs and devices to market, including frontline treatments for Parkinson’s, Huntington’s, and rare neuromuscular diseases.
What makes CHeT stand out is its all-in-one model. Trial coordination, clinical materials, outcomes measurement, data analytics, and regulatory support all operate in concert, allowing the center to design and run complex, multisite trials that many organizations consider too risky or too complicated.
Today, under the leadership of neurologist Chad Heatwole, CHeT is expanding that impact by pairing patient-reported outcomes with wearable sensors, smartphone apps, and decentralized study visits. The goal: to “measure what matters to patients” and make it easier for people everywhere—not just those who live near major academic medical centers—to participate in cutting-edge research.
Get the full story of CHeT’s history and its next frontier, from brain–computer interfaces to AI-powered trial modeling.
